Immune Modulators and IVF

Immune Modulators in Women Undergoing IVF----a Prospective Study

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02626702

Enrollment

500

Registered

2015-12-10

Start date

2015-07-31

Completion date

2019-08-31

Last updated

2019-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

In Vitro Fertilization

Keywords

immune modulators, IVF outcomes, relationship

Brief summary

Exploring the immune mediators of early pregnancy prospectively may help to identify new early interventions that will increase the likelihood of success and help women make informed decisions regarding their pregnancies.

Detailed description

Sera will be obtained from 500 women undergoing IVF at five time periods: cycle Day 2, post HCG, Day 24, Day 28, and/or Day 35.Aliquots of sera will be tested by commercial ELISA kits for concentrations of immune modulators suggestive to be predictive of IVF outcome, such as cytokines (interleukins, tumor necrosis factor, and interferon), neurotrophins (BDNF), protease inhibitors (HE4) and insulin-like growth factors (IGF-1, IGF-2, IGFBP). The results will be correlated with IVF outcomes.

Interventions

OTHERObservational

Excess blood from subjects will be analyzed to explore the relationship between Immune Modulators and IVF outcomes.

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 44 Years

Healthy volunteers

Inclusion criteria

* All fresh transfers

Exclusion criteria

* PGD

Design outcomes

Primary

Measure	Time frame
To explore the relationship between immune mediators and IVF outcome prospectively in women who receive in vitro fertilization treatment.	35 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026